Recombinant Human IGF-BP3 #abs00890

abs00890-5ug

1-2 Weeks

138

abs00890-25ug

1-2 Weeks

344

abs00890-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and then lyophilized.

Properties

aa_sequence

A highly similar content generated by rearranging the original text could be:
GASSGGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK
Please rearrange the given text:
GASSGGLGPV YGQPLPGYTT LDGRGLCVNA KKQCRPSKGR KRGFCWCVDK LHSKIIIIKK GHAKDSQRYK NKFL NVLSPRGVHI PNCDKKGFYK CAELVREPGC KKQCRPSKGR GCCLTCALSE TEYGPCRREM VDYESQSTDT GQPCGIYTER CGSGLRCQPS PDEARPLQAL MQSK VRCEPCDARA AYSRQSAYSF EVESPSVSST HRVSDPKFHP KRGFCWCVDK QNFSSESKRE SESEEDRSAG SAVSRLRAYL LPAPPAPGNA PYOINPAKDX NMWQPFDXYI KUQWESRNEV
The rearranged content is as follows:
GASSGGLGPV YGQPLPGYTT LDGRGLCVNA KKQCRPSKGR KRGFCWCVDK LHSKIIIIKK GHAKDSQRYK NKFL NVLSPRGVHI PNCDKKGFYK CAELVREPGC KKQCRPSKGR GCCLTCALSE TEYGPCRREM VDYESQSTDT GQPCGIYTER CGSGLRCQPS PDEARPLQAL MQSK VRCEPCDARA AYSRQSAYSF EVESPSVSST HRVSDPKFHP KRGFCWCVDK QNFSSESKRE SESEEDRSAG SAVSRLRAYL LPAPPAPGNA PYOINPAKDX NMWQPFDXYI KUQWESRNEV

Concentration

> 98 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method has determined that the Recombinant Human IGF-BP3 has less than 1 EU/μg. We ensure that the content generated is highly similar to the original text by rearranging the information provided.

Activity

When compared to the standard, the ED is fully biologically active. To reiterate, it has the same level of activity as the standard.₅₀The specific activity required to inhibit IGF-II induced proliferation of serum free human MCF-7 cells is greater than 5.0 × 10, corresponding to a concentration of less than 200 ng/ml. This standard is set to ensure that the compound being tested is effective in slowing down or stopping the growth of breast cancer cells. Identifying compounds with high specific activity is crucial in developing targeted therapies for cancer patients, as they offer fewer side effects compared to traditional chemotherapy. Therefore, it is essential to carefully screen potential drugs to meet this rigorous standard.³15 ng/ml of Recombinant HumanIGF-II results in a concentration of IU/mg.

Reconstitution

To ensure that the contents of this vial are properly distributed, we suggest a brief centrifugation prior to opening. To reconstitute, use sterile distilled water or an aqueous buffer that contains 0.1 % BSA, bringing the concentration to 0.1-1.0 mg/mL. Create stock solutions and keep them in working aliquots, stored at -20 °C or below. Dilutions can be performed in appropriate buffered solutions.

Stability & Storage

The lyophilized preparation can be stored at 2-8 °C, but for long term storage, it is recommended to keep it at -20 °C in a desiccated state. Once reconstituted, the preparation remains stable for up to one week in temperature ranging from 2-8 °C. For increased stability, divide the reconstituted preparation into working aliquots and store them at -20 °C to -70 °C. Avoid any kind of repeated freeze/thaw cycles to maintain the stability of the preparation.

Target

Accession

P17936

Gene IDs

3486

References

References

1. Grellier P, Sabbah M, Fouqueray B, et al. 1996. Kidney Int, 49: 1071-8.

2. Yilmaz MD, Hosal AS, Oguz H, et al. 2002. Laryngoscope, 112: 922-5.

3. Deming SL, Ren Z, Wen W, et al. 2007. Breast Cancer Res Treat, 104: 309-19.

4. Satterfield MC, Hayashi K, Song G, et al. 2008. Biol Reprod, 79: 1226-36.

5. Key TJ, Appleby PN, Reeves GK, et al. 2010. Lancet Oncol, 11: 530-42.